Levomepromazine

CHEMBL1764 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

328.5 g/mol

LogP

4.7

Phase

4

This phenothiazine antipsychotic and sedative is used to treat psychosis, severe anxiety, agitation, and to provide pain relief and sedation in palliative care settings. It has both antipsychotic and antiemetic properties, making it useful for nausea and vomiting as well.

분자량

328.5000 g/mol

LogP

4.70

TPSA

41.00 Å²

리핀스키 5의 법칙

통과

치료 영역

Schizophrenia Bipolar Disorder Generalized Anxiety Disorder

작용 기전

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1ccc2c(c1)N(C[C@H](C)CN(C)C)c1ccccc1S2

InChI

InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1

Molecular Formula

C19H24N2OS

HBD / HBA

- / 4

회전 가능 결합

5

무거운 원자

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This phenothiazine antipsychotic and sedative is used to treat psychosis, severe anxiety, agitation, and to provide pain relief and sedation in palliative care settings. It has both antipsychotic and antiemetic properties, making it useful for nausea and vomiting as well.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Levomepromazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1764. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 72287. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Levomepromazine PillFYI에서

구조

핵심 데이터

분자식: C19H24N2OS

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.